Nature Communications · 2018 · 149 citations · 53 references
MedicineImmunologyOncologyInflammationSignal TransductionTumor MicroenvironmentAngiogenesisChemokine NetworksChemokine SignalingInflammatory MediatorsInflammatory SignalingLeukocyte RecruitmentAngiogenic Factor ExpressionChemokine BiologyChemokine ResponsesExtravasation MechanismsInflammatory Cytokine ProductionInflammatory Cytokine SecretionInflammatory Mediators Of AngiogenesisLive Imaging
Abstract Recruitment of circulating monocytes is critical for tumour angiogenesis. However, how human monocyte subpopulations extravasate to tumours is unclear. Here we show mechanisms of extravasation of human CD14 dim CD16 + patrolling and CD14 + CD16 + intermediate proangiogenic monocytes (HPMo), using human tumour xenograft models and live imaging of transmigration. IFNγ promotes an increase of the chemokine CX3CL1 on vessel lumen, imposing continuous crawling to HPMo and making these monocytes insensitive to chemokines required for their extravasation. Expression of the angiogenic factor VEGF and the inflammatory cytokine TNF by tumour cells enables HPMo extravasation by inducing GATA3-mediated repression of CX3CL1 expression. Recruited HPMo boosts angiogenesis by secreting MMP9 leading to release of matrix-bound VEGF-A, which amplifies the entry of more HPMo into tumours. Uncovering the extravasation cascade of HPMo sets the stage for future tumour therapies.
53
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Rosandra N. Kaplan, Rebecca D. Riba, Stergios Zacharoulis et al. · Nature · 2005 · 3.2K citations · Full text
Medicine, Cell Biology, Hematology +14
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Bin‐Zhi Qian, Jiufeng Li, Hui Zhang et al. · Nature · 2011 · 2.9K citations · Full text
Medicine, Cancer Biology, Oncology +14
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Vijay Shankaran, Hiroaki Ikeda, Allen T. Bruce et al. · Nature · 2001 · 2.8K citations
Life Sciences, Immunology, Oncology +12